This evidence summary reviews the comparative clinical effectiveness of proprotein convertase subtilisin/kexin type 9 inhibitor for the treatment of adults with familial hypercholesterolemia or cardiovascular disease and who require additional lowering of low-density lipoprotein cholesterol levels.
Article InformationCorresponding Author: Jeffrey A. Tice, MD, Division of General Internal Medicine, Department of Medicine, University of California San Francisco, 1545 Divisadero St, Box 0320, San Francisco, CA 94143-0320 (email@example.com).
Published Online: December 14, 2015. doi:10.1001/jamainternmed.2015.7248.
Conflict of Interest Disclosures: None reported.
Additional Information: The New England Comparative Effectiveness Public Advisory Council is a program of the Institute for Clinical and Economic Review and is supported by grants from the New England States Consortium Systems Organization and the Laura and John Arnold Foundation.
Additional Contributions: We acknowledge the contributions of the following individuals to the development of this article: Kirsten Bibbins-Domingo, MD, PhD, MAS, Pamela G. Coxson, PhD, Joanne Penko, MS, MPH, and David Guzman, MSPH, of the University of California San Francisco; Andrew E. Moran, MD, of Columbia University; and Daniel A. Ollendorf, PhD, Courtney Cunningham, MPH, Erin Lawler, Matt Seider, and Richard Chapman, PhD, of the Institute for Clinical and Economic Review.